Middle East And Africa Biguanide Market Size

Statistics for the 2023 & 2024 Middle East And Africa Biguanide market size, created by Mordor Intelligence™ Industry Reports. Middle East And Africa Biguanide size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Middle East And Africa Biguanide Industry

Middle East And Africa Biguanide Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 311.96 Million
Market Size (2029) USD 370.86 Million
CAGR (2024 - 2029) 3.52 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Middle East And Africa Biguanide Market Analysis

The Middle East And Africa Biguanide Market size is estimated at USD 311.96 million in 2024, and is expected to reach USD 370.86 million by 2029, growing at a CAGR of 3.52% during the forecast period (2024-2029).

Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.

As Type 2 diabetes is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients, the role of glucose control has been emphasized to improve the prognosis. Metformin is the first-line choice for the management of hyperglycemia in T2DM. Besides being an important glucose-lowering agent, metformin also has significant anti-inflammatory. 

Therefore, metformin has been a potential candidate for treating patients affected by COVID-19 infection, with type 2 diabetes, as well as an excellent antidiabetic (glucose-lowering) agent during COVID-19 pandemic times. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

MIDDLE EAST AND AFRICA BIGUANIDE MARKET Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)